Article
Oncology
Diana Rose E. Ranoa, Preeti Sharma, Claire P. Schane, Amber N. Lewis, Edward Valdez, Venkata V. V. R. Marada, Marlies Hager, Will Montgomery, Steven P. Wolf, Karin Schreiber, Hans Schreiber, Keith Bailey, Timothy M. Fan, Paul J. Hergenrother, Edward J. Roy, David M. Kranz
Summary: The use of CAR-T cell therapy against blood cancers has been successful, but its efficacy against solid tumors has been limited. By using a mouse ovarian cancer cell line, researchers found that CAR-T cell therapy can effectively inhibit the growth of solid tumors, with the most effective CAR having the highest affinity for the antigen.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Immunology
Hongtai Shi, Andi Li, Zhenyu Dai, Jiao Xue, Qi Zhao, Jiyuan Tian, Dandan Song, Hao Wang, Jianan Chen, Xiaokang Zhang, Kaisong Zhou, Huafeng Wei, Songbing Qin
Summary: This study aimed to explore whether IL-15 modification would increase the antitumor activity of CLDN18.2-targeting CAR-T cells. The results showed that IL-15 modification improved the expansion and viability of CAR-T cells in vitro and suppressed the growth of CLDN18.2-positive tumors in vivo. Furthermore, combined with lymphodepleting preconditioning, IL-15-modified CAR-T cells exhibited superior antitumor activity and prolonged survival.
FRONTIERS IN IMMUNOLOGY
(2023)
Editorial Material
Hematology
Rawan G. Faram, Marco L. Davila
Summary: The CAR-HEMATOTOX predictive model by Rejeski et al in this issue of Blood can identify patients at highest risk of hematologic toxicity following CD19-directed chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory large B-cell lymphoma.
Article
Biochemistry & Molecular Biology
Sachiko Hirobe, Keisuke Imaeda, Masashi Tachibana, Naoki Okada
Summary: In this study, we investigated the effects of disulphide bonding and glycosylation on the function of CAR-expressing T cells. We found that disulphide bonds and N-linked glycosylation influenced CAR expression and CAR-T cell activity, providing insights for future CAR design.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Immunology
Sun Il Choi, Jinlong Yin
Summary: Glioblastoma (GBM) is the most common malignant brain tumor, and alternative tumor-specific therapies are urgently needed. Chimeric antigen receptor (CAR) T cell therapy shows promise for hematological malignancies, but its effectiveness for solid tumors, especially GBM, needs improvement. This review discusses strategies for enhancing CAR T cell effectiveness in GBM treatment.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, Research & Experimental
Catherine T. Le, Logan V. Vick, Craig Collins, Cordelia Dunai, Michael K. Sheng, Lam T. Khuat, Isabel Barao, Sean J. Judge, Ethan G. Aguilar, Brendan Curti, Maneesh Dave, Dan L. Longo, Bruce R. Blazar, Robert J. Canter, Arta M. Monjazeb, William J. Murphy
Summary: Memory T cells can be activated through bystander activation with cytokine signaling, but this response is inhibited by the PD-1 pathway. PD-1 blockade reverses this inhibition, but leads to activation-induced cell death and eventual loss of T cells.
Review
Immunology
Haolong Lin, Jiali Cheng, Wei Mu, Jianfeng Zhou, Li Zhu
Summary: CAR-T cell therapy has shown remarkable success in antitumor treatments, particularly against hematological malignancies. The development of universal CAR-T (UCAR-T) cell therapy may overcome current limitations, with a focus on safety, efficiency, and potential complementary immune cells. The landscape and prospects of UCAR-T cell therapy are explored through a comprehensive overview of progress and challenges.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Lusine Hovhannisyan, Carsten Riether, Daniel M. Aebersold, Michaela Medova, Yitzhak Zimmer
Summary: CAR T cell-based therapies have revolutionized the treatment of hematological malignancies. However, the treatment of solid tumors with CAR T cells remains challenging. Radiation therapy, in combination with immune checkpoint inhibitors, has shown promising results in clinical trials. Combining radiation therapy with CAR T cell therapy may overcome the limitations in solid tumor treatment. This review discusses the potential and risks of this combination in cancer patients.
Review
Immunology
Wenshuai Li, Xuanxuan Pan, Lirong Chen, Haoshu Cui, Shaocong Mo, Yida Pan, Yuru Shen, Menglin Shi, Jianlin Wu, Feifei Luo, Jie Liu, Na Li
Summary: Adoptive cell therapy (ACT) using chimeric antigen receptor (CAR)-modified T cells has shown remarkable efficacy against hematological malignancies, but its success in solid tumors is limited by factors such as easy recurrence and poor efficacy. The effector function and persistence of CAR-T cells are critical to the success of therapy and are modulated by metabolic and nutrient-sensing mechanisms. Moreover, the immunosuppressive tumor microenvironment (TME) can lead to T cell exhaustion and compromise the efficacy of CAR-T cells. This review discusses the metabolic characteristics of T cells and potential metabolic approaches to improve the efficacy and persistence of CAR-T cells.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Ashanti Concepcion Uscanga-Palomeque, Ana Karina Chavez-Escamilla, Cynthia Aracely Alvizo-Baez, Santiago Saavedra-Alonso, Luis Daniel Terrazas-Armendariz, Reyes S. Tamez-Guerra, Cristina Rodriguez-Padilla, Juan Manuel Alcocer-Gonzalez
Summary: This paper reviews the latest developments in CAR-T cells in cancer treatment, including the structure and manufacturing methods of different generations and variants. The challenges and limitations of CAR-T technology in treating hematological and solid cancer are discussed, as well as the use of CAR technology in other immune cells. The paper concludes that CAR-T cells have the potential to treat not only cancer but also other chronic diseases.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Nga T. H. Truong, Tessa Gargett, Michael P. Brown, Lisa M. Ebert
Summary: CAR-T cell therapy is a promising approach for cancer treatment, especially effective for blood cancers but less so for solid cancers. Chemotherapy not only kills cancer cells but also modulates the immune system, potentially influencing the manufacturing and anti-cancer activity of CAR-T cells. Further research is needed to explore the optimal integration of CAR-T cell therapies with cytotoxic chemotherapy for solid cancers.
Article
Radiology, Nuclear Medicine & Medical Imaging
Sophia Huang, Dorine de Jong, Jeeban P. Das, Reginald Scott Widemon, Brian Braumuller, Jacienta Paily, Aileen Deng, Connie Liou, Tina Roa, Alice Huang, Hong Ma, Belinda D'Souza, Jay Leb, Jade L'Hereaux, Pamela Nguyen, Lyndon Luk, Mark Francescone, Randy Yeh, Valerie Maccarrone, Laurent Dercle, Mary M. Salvatore, Kathleen M. Capaccione
Summary: CAR T cell therapy is a revolutionary immunotherapy for hematologic cancers, but little is known about the radiographic presentation of common side effects. Early and accurate recognition of these side effects is crucial for radiologists and patients.
ACADEMIC RADIOLOGY
(2023)
Article
Hematology
Jennifer A. H. Bell, Gregory A. Jeffries, Christine I. Chen
Summary: With the increasing number of approved CAR-T products and eligible patients, manufacturing capacity and institutional infrastructure need to keep up. Many cell therapy programs face the difficult task of prioritizing patients for treatment, requiring an ethical framework for fair decision-making.
Review
Hematology
Rajat Bansal, Ran Reshef
Summary: CAR T cell therapy has shown impressive response rates in refractory B-cell malignancies, but faces challenges in solid malignancies. Experimental strategies combining small molecules and monoclonal antibodies are being explored to overcome resistance mechanisms to CAR T cells.
Review
Immunology
Xiaomin Zhang, Hui Zhang, Huixuan Lan, Jinming Wu, Yang Xiao
Summary: In the past decade, novel therapeutic agents have substantially improved the survival outcome of multiple myeloma (MM) patients, but MM remains incurable and almost all patients relapse due to drug resistance. B cell maturation antigen (BCMA)-targeted CAR-T cell therapy has brought new hopes for relapsed/refractory MM, but challenges such as resistance and limited accessibility hinder its broad clinical application. This review discusses the limitations of CAR-T cell therapy in MM and summarizes optimization strategies to overcome these challenges.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Thivyan Thayaparan, Roseanna M. Petrovic, Daniela Y. Achkova, Tomasz Zabinski, David M. Davies, Astero Klampatsa, Ana C. Parente-Pereira, Lynsey M. Whilding, Sjoukje J. C. van der Stegen, Natalie Woodman, Michael Sheaff, Jennifer R. Cochran, James F. Spicer, John Maher
Review
Oncology
Astero Klampatsa, Andrew R. Haas, Edmund K. Moon, Steven M. Albelda
Article
Dermatology
Richard W. Davis, Emmanouil Papasavvas, Astero Klampatsa, Mary Putt, Luis J. Montaner, Melissa J. Culligan, Sally McNulty, Joseph S. Friedberg, Charles B. Simone, Sunil Singhal, Steven M. Albelda, Keith A. Cengel, Theresa M. Busch
LASERS IN SURGERY AND MEDICINE
(2018)
Article
Pathology
Lauren E. Rosen, Theodore Karrison, Vijayalakshmi Ananthanarayanan, Alexander J. Gallan, Prasad S. Adusumilli, Fouad S. Alchami, Richard Attanoos, Luka Brcic, Kelly J. Butnor, Francoise Galateau-Salle, Kenzo Hiroshima, Kyuichi Kadota, Astero Klampatsa, Nolween Le Stang, Joerg Lindenmann, Leslie A. Litzky, Alberto Marchevsky, Filomena Medeiros, M. Angeles Montero, David A. Moore, Kazuki Nabeshima, Elizabeth N. Pavlisko, Victor L. Roggli, Jennifer L. Sauter, Anupama Sharma, Michael Sheaff, William D. Travis, Wickii T. Vigneswaran, Bart Vrugt, Ann E. Walts, Melissa Y. Tjota, Thomas Krausz, Aliya N. Husain
Article
Biochemistry & Molecular Biology
Richard W. Davis, Emma Snyder, Joann Miller, Shirron Carter, Cassandra Houser, Astero Klampatsa, Steven M. Albelda, Keith A. Cengel, Theresa M. Busch
PHOTOCHEMISTRY AND PHOTOBIOLOGY
(2019)
Article
Oncology
Shaun M. O'Brien, Astero Klampatsa, Jeffrey C. Thompson, Marina C. Martinez, Wei-Ting Hwang, Abishek S. Rao, Jason E. Standalick, Soyeon Kim, Edward Cantu, Leslie A. Litzkys, Sunil Singhal, Evgeniy B. Eruslanov, Edmund K. Moon, Steven M. Albelda
CANCER IMMUNOLOGY RESEARCH
(2019)
Article
Oncology
Astero Klampatsa, Shaun M. O'Brien, Jeffrey C. Thompson, Abhishek S. Rao, Jason E. Stadanlick, Marina C. Martinez, Maria Liousia, Edward Cantu, Keith Cengel, Edmund K. Moon, Sunil Singhal, Evgeniy B. Eruslanov, Steven M. Albelda
Article
Physiology
Toni Kimura, James Monslow, Astero Klampatsa, Michael Leibowitz, Jing Sun, Maria Liousia, Patrick Woodruff, Edmund Moon, Leslie Todd, Ellen Pure, Steven M. Albelda
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
(2019)
Review
Immunology
Paraskevi Dimou, Sumita Trivedi, Maria Liousia, Reena R. D'Souza, Astero Klampatsa
Summary: Precision-cut tumor slices (PCTS) are important ex vivo human tumor models that allow for the study of individual patient responses to targeted immunotherapies. This review provides an overview of different human tumor models and focuses on the unique characteristics of PCTS. The review outlines the standard procedures for generating and maintaining PCTS and discusses their application in preclinical research to understand cytotoxic T cell function and predict patient responses to targeted therapies. The advantages and limitations of PCTS models are also discussed. PCTS are expected to be a significant tool for better patient stratification and personalized medicine.
Review
Biotechnology & Applied Microbiology
Astero Klampatsa, Vivian Dimou, Steven M. Albelda
Summary: Initial trials with anti-MSLN CAR-T cells have shown safety but limited efficacy. Enhancing tumor infiltration and persistence, improving safety profiles, combining with standard therapies, and utilizing regional delivery routes could potentially make anti-MSLN CAR-T cells more effective in treating solid malignancies.
EXPERT OPINION ON BIOLOGICAL THERAPY
(2021)
Article
Oncology
Astero Klampatsa, Daniela Y. Achkova, David M. Davies, Ana C. Parente-Pereira, Natalie Woodman, James Rosekilly, Georgina Osborne, Thivyan Thayaparan, Andrea Bille, Michael Sheaf, James F. Spicer, Juliet King, John Maher
Meeting Abstract
Pathology
Lauren E. Rosen, Vijayalakshmi Ananthanarayanan, Alexander Gallan, Melissa Yuwono Tjota, Richard Attanoos, Fouad S. Alchami, Luka Brcic, Kelly Butnor, Kenzo Hiroshima, Astero Klampatsa, Leslie Litzky, Alberto M. Marchevsky, Filomena Medeiros, M. Angeles Montero-Fernandez, David A. Moore, Kazuki Nabeshima, Elizabeth N. Pavlisko, Anupama Sharma, Michael Sheaff, Ann E. Walts, Francoise Galateau, Nolwenn Le Stang, Thomas Krausz, Aliya N. Husain
Meeting Abstract
Medicine, Research & Experimental
Lauren E. Rosen, Vijayalakshmi Ananthanarayanan, Alexander Gallan, Melissa Yuwono Tjota, Richard Attanoos, Fouad S. Alchami, Luka Brcic, Kelly Butnor, Kenzo Hiroshima, Astero Klampatsa, Leslie Litzky, Alberto M. Marchevsky, Filomena Medeiros, M. Angeles Montero-Fernandez, David A. Moore, Kazuki Nabeshima, Elizabeth N. Pavlisko, Anupama Sharma, Michael Sheaf, Ann E. Walls, Francoise Galateau, Nolwenn Le Stang, Thomas Krausz, Aliya N. Husain
LABORATORY INVESTIGATION
(2017)
Review
Medicine, Research & Experimental
Elizabeth R. Hawkins, Reena R. D'Souza, Astero Klampatsa
Summary: CAR T-cell therapy engineers T-cells to target tumors more effectively, but faces challenges in treating solid tumors. Researchers are currently exploring methods such as secreting cytokines or targeting multiple tumor antigens to enhance the function of CAR T-cells in the tumor microenvironment.
BIOLOGICS-TARGETS & THERAPY
(2021)